Janssen Research & Development, LLC
$345.1M 1,588 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Amgen Inc.
Amgen Inc. reported $343,047,599.02 across General Payments, Research, and Ownership to 474,864 physicians and teaching hospitals across 479,804 transactions.
- $343.0M Top 1% payer
- All-tracks total
- 479,804 Top 1% volume
- Transactions
- 474,864 Top 1% reach
- Recipients
- +$18.1M
- General Payments vs PY2023
Amgen Inc. reported $343,047,599.02 across all CMS Open Payments tracks (General + Research + Ownership) to 474,864 physicians and teaching hospitals in Program Year 2024 - ranking #11 of 1,925 reporting manufacturers (2.5% of the all-tracks industry total); General Payments alone were $44,921,708.09, averaging $722.41 per recipient.
How Amgen Inc.'s $343.0M all-tracks total breaks down
Amgen Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer amgen-inc Amgen Inc.
$343.0M · #11/1,925 · 2.5% industry · PY2024
- TOT $343.0M
- RANK #11
- SHARE 2.5%
- TXN 479,804
- RCP 474,864
- CAT 9
- GEN $44.9M
- ΔGEN +$18.1M
- TOP1 6.6%
- PY 2024
Volume peers
Nearest volume peer: Janssen Research & Development, LLC ($345.1M)
Amgen Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Amgen Inc.'s CMS-reported General Payments increased by $18.1M (+67.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AMGEN INC.PY2023: AMGEN INC.PY2024: Amgen Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $26,813,891.67
- PY2024
- $44,921,708.09
What the Data Shows for Amgen Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Amgen Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
9,958 transactions worth $21.0M make "Compensation for Services Other Than Consulting" the top general-payment category in the 9-category breakdown below, 46.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Amgen Inc.'s 9-category general-payment breakdown at $21.0M, 46.8% of the reported total.
Amgen Inc. reports 9 general-payment categories - the top three are Compensation for Services Other Than Consulting (46.8%), Food and Beverage (24.8%), and Consulting Fee (12.8%). The remaining 6 categories make up 15.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Amgen Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Amgen Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $21.0M | 9,958 | 46.8% |
| Food and Beverage | $11.2M | 451,412 | 24.8% |
| Consulting Fee | $5.8M | 2,016 | 12.8% |
| Travel and Lodging | $3.4M | 9,846 | 7.5% |
| Royalty or License | $2.9M | 26 | 6.4% |
| Charitable Contribution | $530.1K | 8 | 1.2% |
| Grant | $100.0K | 3 | 0.2% |
| Space Rental or Facility Fees | $92.4K | 36 | 0.2% |
| Education | $23.0K | 1,559 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $4,613,891.15 (10.3%) of $44,921,708.09 in this company's General Payments records across 118,976 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Amgen Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Dana-Farber Cancer Institute
$2,969,310.98 across 6 reported transactions
- 2
John Stone
$524,910.46 across 21 reported transactions
- 3
Massachusetts General Hospital
$395,000.00 across 1 reported transactions
- 4
Brian Jay Druker
$379,930.11 across 78 reported transactions
- 5
Terry Jay Smith
$344,739.60 across 105 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Amgen Inc. ranks #11 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,758 of 1,838 by HHI (bottom 4% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Organon Llc : $4.7M total payments, HHI 59
- Coastal Medical Technologies Llc : $69.5K total payments, HHI 58
- EMD Serono, Inc. : $10.0M total payments, HHI 58
- Abbvie Inc. : $156.7M total payments, HHI 57
- Journey Medical Corporation : $64.6K total payments, HHI 55
- Eisai Inc. : $7.1M total payments, HHI 55
- Amgen Inc. (this company) : $44.9M total payments, HHI 55
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) : $10.8M total payments, HHI 52
- Mylan Specialty L.P. : $1.4M total payments, HHI 51
- Virtus Pharmaceuticals LLC : $19.8K total payments, HHI 50
- Madrigal Pharmaceuticals : $4.5M total payments, HHI 49
- Electronic Waveform Lab, Inc. : $32.0K total payments, HHI 47
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Amgen Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Amgen Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Amgen Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Midmark Corporation
$386.1M 378 recipients
Compare payment profiles
Genentech, Inc.
$400.6M 2,544 recipients
Compare payment profiles
AstraZeneca Pharmaceuticals LP
$428.2M 858,609 recipients
Compare payment profiles
E.R. Squibb & Sons, L.L.C.
$251.5M 236,558 recipients
Compare payment profiles
GlaxoSmithKline, LLC.
$242.1M 341,439 recipients
Compare payment profiles
Put this to use
Amgen Inc. ranks #11 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Amgen Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Amgen Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.